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INTRODUCTION
Immunoglobulin A nephropathy (IgAN) is the most com-
mon type of primary glomerulonephritis in the world among
patients undergoing renal biopsy. It is known to be an impor-
tant cause of end stage renal disease. The actuarial renal sur-
vival at 10 yr in adults with IgAN is about 80-85% accord-
ing to several epidemiologic studies of Asian countries (1-3).
Although several clinical factors such as severe proteinuria,
arterial hypertension, elevated serum creatinine level (4-6),
and the severity of glomerular sclerosis and interstitial fibro-
sis on the renal pathology (7) have been thought to be relat-
ed to the progression of IgAN, it is not clear why some of
patients develop progressive disease, while the others do not.
It has been suggested that genetic factors may contribute
not only to the susceptibility to IgAN but also to its pro-
gression. There have been so many genetic association stud-
ies on the candidate genes of IgAN progression, of which
the most widely studied have been polymorphisms of genes
involved in the renin-angiotensin system (RAS), including
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We determined the relationship between the progression of immunoglobulin A ne-
phropathy (IgAN) and the A1818T polymorphism in intron 2 of Angiotensin II type
2 receptor (AT2R) gene, which might play protective roles in the pathogenesis of
IgAN. Patients with biopsy-proven IgAN were recruited from the registry of the Pro-
gressive REnal disease and Medical Informatics and gEnomics Research (PRE-
MIER) which was sponsored by the Korean Society of Nephrology. A1818T poly-
morphism of AT2R gene was analyzed with PCR-RFLP method and the associa-
tion with the progression of IgAN, which was defined as over 50% increase in base-
line serum creatinine level, was analyzed with survival analysis. Among the 480 patients
followed for more than 10 months, the group without T allele had significantly high-
er rates of progression of IgAN than the group with T allele (11.4% vs. 3.9%, p=0.024),
although there were no significant differences in the baseline variables such as ini-
tial serum creatinine level, the degree of proteinuria, and blood pressure. In the Cox’s
proportional hazard model, the hazard ratio of disease progression in the patients
with T allele was 0.221 (95% confidence interval for Exp(B): 0.052-0.940, p=0.041)
compared to that of without T allele. In conclusion, A1818T polymorphism of AT2R
gene was associated with the progression of IgAN. 
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insertion/deletion (I/D) polymorphisms of angiotensin con-
verting enzyme (ACE) gene (10), and angiotensinogen gene
polymorphisms (11). However, results of these studies were
inconsistent.
Several experimental studies have suggested that as an
another important part of the RAS, counter-regulatory to
the vasoconstrictor action of the angiotensin II via AT1R,
angiotensin II type 2 receptor (AT2R) might have a protec-
tive role in the ischemic kidney injury (12) and that tubular
expression of AT2R and imbalance to AT1R could be relat-
ed to the pathogenesis of IgAN (13). Additionally, accord-
ing to recent association study in type 1 diabetic patients,
among the polymorphisms of X-chromosomal AT2R gene,
A1818T polymorphism was reported to be related to the
kidney function (14). Therefore, we hypothesize that A1818T
polymorphism of AT2R gene may be involved in the pro-
gression of IgAN.
MATERIALS AND METHODS
Study subjects
This study was approved by the Institutional Review Board
in Seoul National University Hospital and other participat-
ed hospitals before gathering the data. Informed consents
were obtained from the patients. The subjects were enrolled
in the Progressive REnal disease and Medical Informatics
and gEnomics Research (PREMIER) which was sponsored
by the Korean Society of Nephrology since August 2003.
In PREMIER study, 34 hospitals and clinics in Korea par-
ticipated. We analyzed the clinical data of 4,406 patients
aged 15 yr or more with glomerulonephritis diagnosed by
renal biopsy from May 1982 to December 2006. From this
registry, 480 patients with primary IgAN, who were over
15 yr old, had a minimum follow up period of 10 months
were enrolled in this study. Diagnosis of IgAN was based
on established pathologic criteria, including mesangial expan-
sion and the diagnostic presence of IgA as the sole, predom-
inant, or co-dominant immunoglobulin. Patients with evi-
dence of systemic diseases, such as diabetes, chronic liver dis-
ease, or systemic lupus erythematosus, were excluded. One
hundred healthy, randomly selected, age-matched, normoten-
sive subjects without any evidence of renal disease were also
recruited from the Health Promotion Centre of Seoul National
University Hospital as control.
Clinical data 
The participated researchers had selected candidate patients,
and one qualified nurse visited every participated institution
to collect the clinical data at the time of renal biopsy and
during follow-up visits. We gathered the data of age, gen-
der, body mass index (BMI), blood pressure, serum protein
level, serum albumin level, serum cholesterol level, serum
uric acid level, serum creatinine level, the degree of protein-
uria by spot urine protein creatinine ratio (suPCR) at the time
of renal biopsy and medication of RAS inhibitors or steroid
during follow-up period. The hypertension was defined as
systolic blood pressure (SBP) 140 mmHg or higher, diastolic
blood pressure (DBP) 90 mmHg or higher, or taking anti-
hypertensive medication before renal biopsy and the severe
proteinuria were defined as more than 3 of suPCR, respec-
tively. The estimated glomerular filtration rate (eGFR) was
calculated by the modified MDRD equation (15).
Definition of disease progression
The primary end point was an increase of serum creatinine
level by more than 50% of baseline value or initiation of renal
replacement therapy for the end stage renal disease. We defined
the progressive disease as the group of patients of IgAN reach-
ed to the primary end point and stable disease for the others.
The follow-up duration was the duration of time between
renal biopsy and the primary end point or the last follow-up
date. 
Extraction of genomic DNA and genotype determination
Genomic DNA was isolated from peripheral blood using
a Wizard Genomic DNA Purification Kit (Promega, Madi-
son, WI, U.S.A.), according to the manufacturer’s instruc-
tions. Genotyping for the A1818T polymorphism of AT2R
gene was done using methods previously described (16). Briefly
for the region spanning the polymorphism, the minisequenc-
ing primers were 5′ -CTGTATTTTGCAAAACTCCT-3′ and
5′ -TTATGTTAATTTGTTAGGTC-3′ , respectively. The
resulting amplicon was digested using Sau961 restriction
enzyme (Promega), which recognizes the 1818T allele. The
restriction products were then visualized on 2% agarose gels
containing ethidium bromide. Confirmation of genotypes
was done by direct DNA sequencing using the ABI Prism
Big Dye Terminator kit (Applied Biosystems, Foster City,
CA, U.S.A.) of 10% of the study population samples. In all
cases, the genotype determined by PCR restriction frag-
ment length polymorphism assay was identical to that
determined by DNA sequencing.
Statistical analysis 
All data were analyzed using SPSS 12.0 KO for Windows.
Mantel-Haenszel chi-square test was used to detect the dif-
ferences in the genotype distributions of the patients and
controls. The Continuous variables were tested by Student’s
t-test or Mann-Whitney tests and the discrete variables by
chi-square test. To test the significance of various prognostic
factors related to the disease progression, survival analysis
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models were carried out. With the Kaplan-Meier analysis, we
expressed survivorship curve about the difference between
patients with T allele and those without T allele. And then
we analyzed the multivariate analysis with Cox’s model,
adjusted for age, sex, serum creatinine level, the degree of
proteinuria (as a continuous variables, and a discrete vari-
able suPCR <3 or ≥3), the presence of hypertension, and
decreased renal function at the time of diagnosis. 
RESULTS
Genetic distribution in control group and IgAN patient
group
We investigated A1818T polymorphism in intron 2 of
the AT2R gene located on X-chromosome. Table 1 shows
the genotype distribution in control and patients groups.
The genotype distribution was not different between con-
trol and patient groups (χ 2=5.111, p=0.078). This finding
suggested that A1818T polymorphism of AT2R gene was
not associated with susceptibility of IgAN. The genotype
distribution in female control group and in female patient
group did not deviate from Hardy-Weinberg equilibrium
(p>0.05). 
Baseline characteristics of patients with IgAN
Among 480 patients with biopsy-proven IgAN, progres-
sive disease was observed in 47 patients in 9.8% of the pop-
ulation after a follow-up of 30.33±3.34 months (mean±
standard deviation). There was a higher proportion of male
patients in patients with progressive disease than in those
with stable disease. The well-known indicators of poor renal
function, such as lower eGFR and higher serum creatinine
level, higher blood pressure, more severe proteinuria were
observed in progressive disease group, compared to stable
disease group (Table 2). The proportion of patients taking
inhibitors of renin-angiotensin systems and that of patients
with a history of steroid therapy were not different between
2 groups. 
Comparison between patients with T allele and those
without T allele 
Males were less common in patients group with T allele
than in patients group without T allele (38.8% vs. 57.8%
respectively, p=0.001) (Table 3). Patients with the T allele
were significantly younger at the time of kidney biopsy than
those without it (33.36±12.68 vs. 36.61±13.92 respective-
ly, p=0.025) (Table 3). Patients with T allele showed lower
serum uric acid than those without it (5.65±2.01 vs. 6.13
±1.75 respectively, p=0.033) (Table 3). The baseline renal
function, blood pressure, and the proportion of patients tak-
ing inhibitors of RAS or steroid were not different between
patients with the T allele and those without it. The progres-
sion of renal disease was observed in 11.4% (43/334) of pati-
Genotype
Control* 
total
IgAN*
Total Female Male
AA 87 (87) 377 (78.5) 218 (84.5) 159 (71.6)
AT 10 (10) 58 (12.1) 58 (26.1)
TT 3 (3) 45 (9.4) 40 (15.5) 5 (2.3)
Total 100 (100) 480 (100)  258 (100) 222 (100)
Table 1. Genotyping of controls and patients with immunoglob-
ulin A nephropathy (IgAN)   
*χ 2=5.111, p value=0.078, Data are N (%).
*estimated Glomerular Filtration Rate; 
�
Body Mass Index; 
�
Systolic Blood Pressure; 
�Diastolic Blood Pressure; 
‖Protein Creatinine Ratio.
Variables Total patients (N=480) Stable disease (N=433) Progressive disease (N=47) p value
Follow-up duration (month) 30.33±3.34 28.84±18.68 44.74±28.05 <0.001
Age (yr) 35.91±13.72 35.74±13.89 37.58±11.95 0.227
Male (%) 53.8 51.7 73.3 0.007
BMI
�(kg/m
2) 23.43±3.34 23.44±3.36 23.27±3.14 0.94
SBP
�(mmHg) 126.14±19.33 125.30±18.40 135.37±26.14 0.041
DBP
� (mmHg) 79.71±12.88 79.01±12.23 87.46±16.99 0.002
Hypertension (%) 42.5 40.9 64.3 0.018
eGFR* (mL/min/1.73 m
2) 77.47±32.87 80.15±31.60 47.94±32.52 <0.001
eGFR <60 mL/min/1.73 m
2 (%) 29.3 25.7 77.4 <0.001
Serum creatinine (mg/dL) 1.30±1.25 1.19±0.95 2.40±2.59 <0.001
Spot urine PCR
‖ 1.97±3.03 1.90±3.01 2.86±3.20 0.001
Spor urine PCR
‖ >3 (%) 16.3 14.7 33.3 0.009
Serum_albumin (mg/dL) 3.82±0.65 3.85±0.65 3.50±0.56 0.002
Serum total cholesterol (mg/dL) 195.28±72.39 195.99±74.39 186.10±37.59 0.722
Serum uric acid (mg/dL) 6.04±1.81 5.92±1.74 7.83±1.98 <0.001
ACEI/ARB use (%) 65.3 66.2 55.3 0.213
Steroid use (%) 12.2 12.1 13.2 0.797
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ents without the T allele and in 3.9% (4/103) of those with
it (p=0.024) (Table 4). According to sex, there was no sig-
nificant difference in the incidence of progressive renal dis-
ease between patients with the T allele and those without
it. However, it tended to increase in the patients without
the T allele (Table 4). 
Survival analysis 
With a univariate Cox proportional hazard model, the
presence of T allele at AT2R A1818T, female gender, lower
serum creatinine level at the time of kidney biopsy, absence
of hypertension, and suPCR <3 were associated with better
renal prognosis. With multivariate analysis, the presence of
T allele and lower baseline serum creatinine level were inde-
pendent factors associated with better prognosis (Table 5).
The Kaplan-Meier survival curve in Fig. 1 shows that the
survival rate of the patients with the patients with the T
allele is significantly better than those without it. (Logrank
test, p=0.0236).
DISCUSSION
Our study indicated that the A1818T polymorphism of
AT2R gene is an independent prognostic factor for IgAN
but not a significant susceptibility factor for IgAN develop-
ment. To the best of our knowledge, this is the first report
on the association between the A1818T polymorphism and
the prognosis of primary renal disease. Various genetic factors
have been reported to be associated with the susceptibility
or prognosis of IgAN (17). Regarding chronic renal diseases,
*Change of AA allele to AT or TT allele in A1818T polymorphism; 
� per 1 mg/dL.
Variables Variables
Univariate analysis
p value 95% CI Exp (B)
Mutivariate analysis
p value 95% CI Exp (B)
With T allele* 0.025 0.309 0.111-0.862 With T allele* 0.041 0.221 0.052-0.940
Serum creatinine
� <0.001 1.277 1.171-1.394 Serum creatinine
� <0.001 1.901 1.504-2.402
Female gender 0.04 0.511 0.270-0.970
Hypertension 0.043 1.966 1.020-3.790
PCR >3 0.004 2.934 1.398-6.157
Table 5. Predictors for the disease progression of immunoglobulin A nephropathy by the Cox’s proportional hazard model
*Without T allele means A allele (male), AA (female) and the opposite is
with T allele; 
� estimated Glomerular Filtration Rate; 
� Body Mass Index;
�Systolic Blood Pressure; 
‖Diastolic Blood Pressure; 
¶Spot urine Pro-
tein Creatinine Ratio.
Variables Without T allele*
(N=377) 
With T allele*
(N=103) 
p value
Follow-up duration (month) 29.72±27.52 32.59±33.82 0.373
Age (yr) 36.61±13.92 33.36±12.68 0.025
Male (%) 57.8 38.8 0.001
BMI
�(kg/m
2) 23.36±3.23 23.67±3.76 0.511
SBP
� (mmHg) 126.28±19.96 125.64±16.86 0.782
DBP
‖ (mmHg) 79.77±13.21 79.5±11.63 0.863
Hypertension (%) 32 36.3 0.507
eGFR
�(mL/min/1.73 m
2) 78.19±33.33 74.89±31.21 0.375
eGFR <60 mL/min/1.73 m
2 (%) 28.9 31.1 0.715
Serum creatinine (mg/dL) 1.28±1.10 1.38±1.68 0.464
Spot urine PCR
¶ 1.97±2.91 1.98±3.48 0.984
Spot urine PCR
¶ >3 (%) 17.1 13.1 0.412
Serum_albumin (mg/dL) 3.85±0.63 3.72±0.73 0.113
Serum total cholesterol  191.37±63.27 210.55±99.38 0.093
(mg/dL)
Serum uric acid (mg/dL) 6.13±1.75 5.65±2.01 0.033
ACEI/ARB use (%) 64.4 68.8 0.467
Steroid use (%) 12 12.9 0.863
Table 3. Comparison between without T allele and with T allele 
Variables Allele
Stable
disease
Progressive
disease
p value
Total, N=480 (%) Without T allele 334 (88.6) 43 (11.4) 0.024
With T allele 99 (96.1) 4 (3.9)
Male, N=258 (%) Without T allele 186 (85.3) 32 (14.7) 0.127
With T allele 38 (95) 2 (5)
Female, N=222 (%) Without T allele 148 (93.1) 11 (6.9) 0.359
With T allele 61 (96.8) 2 (3.2)
Table 4. Association between the presence of T allele and the
prognosis of immunoglobulin A nephropathy
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Fig. 1. Kaplan-Meier curve of survivorship of immunoglobulin A
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including IgAN and diabetic nephropathy, the genetic poly-
morphisms of genes involved in the renin-angiotensin sys-
tem have been investigated most extensively because of their
essential roles in the pathophysiology of chronic renal diseases
and the renoprotective effects of RAS inhibitors on various
chronic renal diseases, independent of blood pressure lower-
ing effect. The counter-regulatory role of the AT2R in the
biologic effects mediated by the ATR1 has raised a possible
renoprotective role of AT2R and a novel therapeutic target
for IgAN.
The variants of AT2R have been reported to be associated
with various cardiovascular and renal diseases. AT2R gene
null mice showed congenital anomalies of the kidney and
urinary tract (18) and the AT2R gene transfer to the heart
attenuated cardiac hypertrophy and fibrosis in a nongenetic
rat model of hypertension (19). It has been reported that A
to G transition in intron 1 of the AT2R gene was associated
with congenital anomalies of kidney and urinary tract in Cau-
cacians (18), but not in Japanese (16). The association of the
AT2R gene variants with body mass index (20), the protec-
tive role of the AT2R gene in hypertensive subjects (21), and
the association of AT2R gene polymorphism with the devel-
opment of hypertension (22) and salt sensitivity (23) have
been reported. It has been suggested that the +1675 G/A
polymorphism of the AT2R gene is associated with early
structural changes of the heart due to arterial hypertension
(24). The variants of AT2R gene have been reported to be
associated with a lower GFR and a higher pulse pressure in
type 1 diabetes patients (14). Based on the results of this
report, it is thought that the AT2R gene might be associat-
ed with clinical features of primary renal diseases.
Our study indicated that the T allele of the A1818T poly-
morphism of the AT2R gene was associated with better prog-
nosis of IgAN in a relatively large number of patients. How-
ever, further functional studies on the biologic implications
of polymorphism relevant to the pathophysiology of IgAN
are needed to confirm our results. In addition, further genet-
ic research with a large sample sized and a longer follow-up
period is required to determine the interaction between con-
ventional risk factors and various genetic risk factors.
In conclusion, the results of this study suggest that the
A1818T polymorphism of the AT2R gene may be associat-
ed with the prognosis of IgAN, but not with susceptibility
to IgAN and also, these results need to be confirmed in dif-
ferent ethnic groups.
APPENDIX
Members of the PREMIER group: Institutions that par-
ticipated in the study (Investigators). 
Cheju National University Hospital (Eun Hee Jang), Chon-
buk National University Medical School (Won Kim), Chon-
nam National University Medical School (Nam Ho Kim,
Woo Kyun Bae), Chungbuk National University College of
Medicine (Hye Young Kim), Chungnam National Univer-
sity College of Medicine (Young-Tai Shin, Kang Wook Lee,
Ki-Ryang Na), Daegu Catholic University Medical Center
(Ki Sung Ahn), Dankook University Hospital (Jong Tae Cho,
Eun Kyeong Lee), Dong-A University College of Medicine
(Ki Hyun Kim, Wonsuk An, Seong Eun Kim), Ewha Wom-
ans University School of Medicine (Choi Gyu Bog, Seung-
Jung Kim), Gachon University of Medicine and Science
(Woo Kyung Chung, Hyun Hee Lee, Jaeseok Yang, Sejoong
Kim), Gyeongsang National University Hospital (Se-Ho
Chang), Hallym University College of Medicine (Jung Woo
Noh, Young Ki Lee, Seong Gyun Kim, Jieun Oh, Young
Rim Song), Inha University College of Medicine (Moon Jae
Kim, Seoung Woo Lee), Inje University College of Medicine
(Yeong Hoon Kim, Won Do Park), Keimyung university
school of medicine (Hyun Chul Kim, Sung Bae Park), Kon-
kuk University School of Medicine (Kyo-Soon Kim), Korea
University Anam Hospital (Won Yong Cho, Hyung Kyu
Kim, Sang Kyung Jo), Korea University Ansan Hospital
(Cha Dae Ryong, Kang Young Sun), Korea University Col-
lege of Medicine Guro Hospital (Young-Joo Kwon), Kyung-
pook National University School of Medicine (Yong-Lim
Kim, Sun-Hee Park, Chan-Duck Kim), Pochon CHA Uni-
versity College of Medicine (Dong Ho Yang), Pusan Nation-
al University School of Medicine (Ihm Soo Kwak,, Soo Bong
Lee, Dong Won Lee, Sang Heon Song, Eun Young Seoung),
Seoul Medical Center (Su-Jin Yoon), Seoul National Uni-
versity Bundang Hospital (Dong-Wan Chae, Ki Young Na,
Ho Jun Chin), Seoul National University College of Medicine
Boramae Medical Center (Chun Soo Lim, Yoon Kyu Oh),
Seoul National University Hospital (Kook Hwan Oh, Kwon
Wook Joo, Yon-Su Kim, Curie Ahn, Jin Suk Han, Suhngg-
won Kim), Seoul National University Hosptial Clinical Insti-
tute (Hyung Jin Yoon), Sungkyunkwan University School
of Medicine (Kyu-Beck Lee), Sungkyunkwan University
School of Medicine Samsung Medical Center (Yoon Goo
Kim, Jung Eun Lee), Ulsan University College of Medicine,
Asan Medical Center (Sang Koo Lee), Yeungnam Universi-
ty College of Medicine (Jun-Young Do, Jong-Won Park,
Kyung-Woo Yoon), ordered by alphabet.
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